Biogen INC (Put) (BIIB) Market Value Rose While Capital Fund Management Sa Increased Position

October 2, 2018 - By Dolores Ford

Biogen Inc. (NASDAQ:BIIB) LogoInvestors sentiment decreased to 1.02 in 2018 Q2. Its down 0.05, from 1.07 in 2018Q1. It worsened, as 47 investors sold BIIB shares while 316 reduced holdings. 85 funds opened positions while 286 raised stakes. 170.10 million shares or 4.56% less from 178.22 million shares in 2018Q1 were reported. Hbk Investments LP invested in 138,173 shares or 0.36% of the stock. Oregon Public Employees Retirement Fund owns 51,333 shares. Montecito Savings Bank has invested 0.16% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Atria Ltd holds 3,740 shares or 0.05% of its portfolio. Colony Grp Ltd reported 872 shares or 0.01% of all its holdings. Ferguson Wellman Capital Mgmt Inc invested in 0.79% or 78,173 shares. Prio Wealth Partnership accumulated 0.01% or 831 shares. Sumitomo Life invested in 10,688 shares or 0.38% of the stock. Jacobs Levy Equity invested 0.01% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Cue Fincl reported 1,780 shares. Comerica Securities, a Michigan-based fund reported 1,140 shares. 702 are owned by Nichols Pratt Advisers Ltd Liability Partnership Ma. 2,420 are owned by Capital International Ca. Chesley Taft & Limited Liability Co reported 0.1% stake. Metropolitan Life Insur invested 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB).

Since April 25, 2018, it had 1 insider purchase, and 0 sales for $12.96 million activity.

Capital Fund Management Sa increased its stake in Biogen Inc (Put) (BIIB) by 198.62% based on its latest 2018Q2 regulatory filing with the SEC. Capital Fund Management Sa bought 316,200 shares as the company’s stock rose 10.79% with the market. The hedge fund held 475,400 shares of the biological products (no diagnostic substances) company at the end of 2018Q2, valued at $137.98 million, up from 159,200 at the end of the previous reported quarter. Capital Fund Management Sa who had been investing in Biogen Inc (Put) for a number of months, seems to be bullish on the $69.83 billion market cap company. The stock decreased 1.67% or $5.89 during the last trading session, reaching $346.67. About 685,842 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 3.14% since October 2, 2017 and is uptrending. It has underperformed by 12.48% the S&P500.

Capital Fund Management Sa, which manages about $3.92B and $19.17 billion US Long portfolio, decreased its stake in Pioneer Natural Resources Co (Call) (NYSE:PXD) by 85,200 shares to 15,300 shares, valued at $2.90 million in 2018Q2, according to the filing. It also reduced its holding in Fortune Brands Home & Security Inc (Call) (NYSE:FBHS) by 182,574 shares in the quarter, leaving it with 33,700 shares, and cut its stake in Nutrisystem Inc (Call) (NASDAQ:NTRI).

More recent Biogen Inc. (NASDAQ:BIIB) news were published by: which released: “Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives …” on October 02, 2018. Also published the news titled: “Cantor Fitzgerald Starts Coverage of Health Care Stocks” on October 02, 2018.‘s news article titled: “Premarket analyst action – healthcare” with publication date: October 01, 2018 was also an interesting one.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 16 analysts covering Biogen (NASDAQ:BIIB), 11 have Buy rating, 0 Sell and 5 Hold. Therefore 69% are positive. Biogen had 26 analyst reports since April 5, 2018 according to SRatingsIntel. The stock has “Hold” rating by RBC Capital Markets on Tuesday, April 24. The rating was downgraded by Robert W. Baird to “Neutral” on Tuesday, July 10. The firm has “Buy” rating by Oppenheimer given on Tuesday, April 24. Guggenheim maintained Biogen Inc. (NASDAQ:BIIB) on Tuesday, April 24 with “Buy” rating. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Overweight” rating by Morgan Stanley on Wednesday, April 25. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Overweight” rating by Morgan Stanley on Wednesday, July 25. The rating was maintained by Canaccord Genuity with “Buy” on Monday, July 23. The rating was maintained by RBC Capital Markets on Wednesday, April 4 with “Hold”. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Thursday, July 26 by UBS. The stock of Biogen Inc. (NASDAQ:BIIB) has “Equal-Weight” rating given on Wednesday, July 25 by Barclays Capital.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News